Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087536 | 0.89 | CYP2A6 (0.50) | RAB9ACHRNA7LTA4HCYP2A6CDK2 | |
| SCHEMBL9546458 | 0.83 | RAB9A (0.43) | RAB9ACHRNA7LTA4HCYP2A6CDK2 | |
| Hydrochloric Acid SCHEMBL6036964 | 0.81 | RAB9A (0.42) | RAB9ACHRNA7LTA4HCYP2A6CDK2 | |
| SCHEMBL3643530 | 0.80 | RAB9A (0.54) | RAB9ALTA4HCDK2FLT4KDM4C | |
| SCHEMBL27316413 | 0.80 | RAB9A (0.50) | RAB9ALTA4HCDK2FLT4GAA | |
| SCHEMBL15055378 | 0.80 | RAB9A (0.50) | RAB9ALTA4HCDK2FLT4LMNA | |
| SCHEMBL4383419 | 0.80 | RAB9A (0.50) | RAB9ALTA4HCDK2FLT4LMNA | |
| SCHEMBL22851453 | 0.78 | RAB9A (0.53) | RAB9ACHRNA7LTA4HCYP2A6CDK2 | |
| SCHEMBL9036375 | 0.77 | RAB9A (0.47) | RAB9ALTA4HCDK2FLT4GAA | |
| SCHEMBL7999576 | 0.77 | HDAC3 (0.53) | RAB9ALTA4HCDK2FLT4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| US-10913735-B2 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-02-09 | — | — | US | disclosed |
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| US-9944640-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-04-17 | — | — | US | disclosed |
| EP-0796847-B1 | Pyridine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO CO LTD (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6017937-A | BACTERICIDE AGAINST HELICOBACTER PYROLI; INHIBITING ACID SECRETION IN STOMACH OF MAN OR MAMMALS, PREVENTING OR CURING ULCER | SHISEIDO CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5859032-A | HAVING ANTIBACTERIAL ACTIVITY AGAINST HELICOBACTER PYLORI | SHISEIDO CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0796847-A1 | Pyridine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0268229-B1 | IMIDAZOLIDINONE COMPOUNDS, PROCESSES FOR PREPARATION THEREOF, COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICAMENTS HAVING THERAPEUTIC VALUE | TANABE SEIYAKU CO., LTD. (JP) | 1992-07-08 | — | — | EP | disclosed |
| CN-1017245-B | Process for preparing imidazolidinone compound | TANABE SEIYAKU CO (JP) | 1992-07-01 | — | — | CN | disclosed |
| US-4886817-A | Imidazolidinones as brain activators | TANABE SEIYAKU CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| CN-87107864-A | Imidazolidinone compound and preparation method thereof | — | 1988-08-31 | — | — | CN | disclosed |
| EP-0268229-A2 | Imidazolidinone compounds, processes for preparation thereof, compositions comprising such compounds, and the use of such compounds for the manufacture of medicaments having therapeutic value | TANABE SEIYAKU CO., LTD. (JP) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | RAB9A 3247/4885CHRNA7 4840/4885LTA4H 3349/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | RAB9A 3247/4885CHRNA7 4840/4885LTA4H 3349/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | RAB9A 2672/4885CHRNA7 4674/4885LTA4H 1340/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | RAB9A 2672/4885CHRNA7 4674/4885LTA4H 1340/4885 |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | RAB9A 502/4885CHRNA7 4456/4885LTA4H 919/4885 |
| US-10913735-B2 | Bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | RAB9A 417/4885CHRNA7 1377/4885LTA4H 3740/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | RAB9A 2672/4885CHRNA7 4674/4885LTA4H 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.